CD141 Monoclonal Antibody (LS17-9), Brilliant Ultra Violet™ 805

Description: The monoclonal antibody LS17-9 recognizes mouse CD141 (Thrombomodulin, BDCA-3), a type I cell surface glycoprotein that binds to and allosterically activates thrombin. This complex cleaves protein C and the Thrombin Activatable Fibrinolysis Inhibitor (TAFI), initiating an important anticoagulant and antifibrinolytic pathway. Although expressed across many tissues and cell types, its highest expression has been reported on the lumenal surface of vascular endothelial cell. In the immune system the highest expression can be observed on monocytes and macrophages. Soluble CD141 is constitutively present in the serum at a very low level, and can be upregulated during inflammation. The anti-inflammatory activity of CD141 results from its ability to block the highly pro-inflammatory activity of thrombin. CD141 prevents chemotaxis and binding of granulocytes to activated endothelium, and inhibits activation of eosinophils and mast cells thereby reducing inflammation. Although human